Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 20/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610973 | 0.81 | LRRK2 (0.42) | LRRK2CYP1A2TTK | |
| SCHEMBL15650272 | 0.80 | LRRK2 (0.39) | LRRK2CYP1A2TTK | |
| SCHEMBL25676497 | 0.79 | LRRK2 (0.44) | LRRK2CYP1A2TTK | |
| SCHEMBL474984 | 0.78 | HPGD (0.34) | — | |
| SCHEMBL23284544 | 0.78 | LRRK2 (0.40) | LRRK2CYP1A2TTK | |
| SCHEMBL15651627 | 0.77 | GAA (0.34) | LRRK2CYP1A2TTK | |
| SCHEMBL15651873 | 0.75 | LRRK2 (0.45) | LRRK2CYP1A2TTK | |
| SCHEMBL20555643 | 0.71 | LRRK2 (0.37) | LRRK2CYP1A2TTK | |
| SCHEMBL25018491 | 0.70 | LRRK2 (0.41) | LRRK2CYP1A2TTK | |
| SCHEMBL4537025 | 0.70 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024240256-A1 | POLYCYCLIC COMPOUNDS AS KINASE INHIBITORS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院上海有机化学研究所 | 2024-11-28 | — | — | WO | disclosed |
| WO-2024240118-A1 | PREPARATION FOR AND USE OF HETEROARYL DERIVATIVES | 广州智睿医药科技有限公司 | 2024-11-28 | — | — | WO | disclosed |
| CN-119019454-A | Preparation and application of heteroaryl derivative | 广州智睿医药科技有限公司 | 2024-11-26 | — | — | CN | disclosed |
| CN-119019402-A | Polycyclic compounds as LRRK2 kinase inhibitors, methods of preparation and uses thereof | 中国科学院上海有机化学研究所 | 2024-11-26 | — | — | CN | disclosed |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2024-11-14 | — | — | US | disclosed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117247387-A | Aromatic heterocyclic compound and preparation method thereof | 上海翊石医药科技有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11214565-B2 | Compound, compositions, and methods | DENALI THERAPEUTICS INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. | 2018-11-15 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-10000482-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2018-06-19 | — | — | US | disclosed |
| US-9637491-B2 | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors | ORIGENIS GMBH (DE) | 2017-05-02 | — | — | US | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180327391-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, MAPT | LRRK2 1/4885CYP1A2 3151/4885TTK 900/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885CYP1A2 3832/4885TTK 154/4885 |
| US-20220119371-A1 | COMPOUND, COMPOSITIONS, AND METHODS | LRRK2, PARK7, SNCA | LRRK2 1/4885CYP1A2 3146/4885TTK 929/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885CYP1A2 3276/4885TTK 101/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LRRK2 1/4885CYP1A2 3832/4885TTK 154/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | LRRK2 1/4885CYP1A2 4088/4885TTK 245/4885 |
| US-11214565-B2 | Compound, compositions, and methods | LRRK2, PARK7, MAPT | LRRK2 1/4885CYP1A2 3151/4885TTK 900/4885 |
| US-20240374606-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | PDXK, PGK1, PGK2 | LRRK2 3283/4885CYP1A2 2440/4885TTK 183/4885 |
| US-10000482-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LRRK2 1/4885CYP1A2 3709/4885TTK 160/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LRRK2 1/4885CYP1A2 3709/4885TTK 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.